Lantus/Lixisenatide Combo Gets FDA Panel Nod, But Not Sanofi's Device

Pen for iGlarLixi should be redesigned to reduce risk of confusion and medication errors, advisory committee members say.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America